Dr. Balamuth is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3401 Civic Center Blvd
Children's Hospital Of Philadelphia - Hem/Onc
Philadelphia, PA 19104Phone+1 215-590-3535Fax+1 215-590-3992
Education & Training
- Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2005 - 2008
- Children's Hospital of PhiladelphiaResidency, Pediatrics, 2002 - 2005
- Yale School of MedicineClass of 2002
Certifications & Licensure
- PA State Medical License 2002 - 2024
- NC State Medical License 2021 - 2022
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy Start of enrollment: 2013 Apr 01
Publications & Presentations
PubMed
- 17 citationsRisk of brainstem necrosis in pediatric patients with central nervous system malignancies after pencil beam scanning proton therapyJ. Vogel, A. Grewal, Shannon O'Reilly, Robert A. Lustig, G. Kurtz
Acta Oncologica. 2019-09-12 - 399 citationsEwing's sarcomaNaomi Balamuth, Richard B. Womer
The Lancet. Oncology. 2010-02-01 - 21 citationsProton therapy for pediatric head and neck malignanciesJennifer Vogel, Stefan Both, Maura Kirk, Hann Hsiang Chao, Rochelle Bagatell
Pediatric Blood & Cancer. 2018-02-01
Press Mentions
- A Pharmacologically-Based Approach to High Dose Methotrexate Administration to Investigate Nephrotoxicity and Acute Kidney Injury Biomarkers in Children and Adolescents with Newly Diagnosed OsteosarcomaMarch 7th, 2021
- Doctors Save Nationally Ranked Junior Cyclist’s Leg from Aggressive Form of Bone CancerMay 29th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: